Close

Phizer (PFE) Will Perform Despite Difficult Second Half - Jefferies

August 9, 2012 1:25 PM EDT
Get Alerts PFE Hot Sheet
Price: $25.86 -0.19%

Rating Summary:
    13 Buy, 20 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 14 | New: 50
Join SI Premium – FREE
Jefferies reiterated their Buy rating on Pfizer (NYSE: PFE) and upped their price target to $26.00 (from $25.00).

“Q2'12 looked almost as tough as it can get,” said analyst Jeffrey Holford, “yet Pfizer delivered a strong beat at the bottom line driven by exceptional cost control and aggressive share repurchases. H2'12 will be tougher still as the worst comps on generics and FX are yet to come.”

However, Holford believes that the failure of bapineuzumab and the delays to Eliquis and tofacitinib are already discounted into expectations, and the shares can continue to perform well from here.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $23.83 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co